isolated or following purification as described elsewhere with minor modification (16) . In short, purified CFU-GM were obtained as follows : mice were injected intraperitoneally with 200 mg/kg cyclophosphamide, marrow cells were removed 3 d later, and the low density cells (<1.077 g/cm3) were retrieved after density cut separation on Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ). The low density cells were then purified further by centrifugal elutriation in a Sanderson Chamber at 4°C rather than 1OsC. In the present studies, the peak CFU-GM-containing fractions elutriated at a slower sedimentation rate (16) (17) (18) (19) (20) ml/min) than previously reported (24-28 ml/min), but the yields and purity of CFU-GM were similar.
Human bone marrow cells were obtained by aspiration from the posterior iliac crest of healthy volunteers who had given informed consent according to the guidelines established by the Human Investigation Committee of the Indiana University School of Medicine. Low density marrow cells were purified on Ficoll-Hypaque and cultured .
Biomolecules and Antibodies
Natural murine (mu) MIP 1 (comprised of a and ,Q peptides) and MIP 2 were isolated from the supernatant fluid of LPS-stimulated RAW 264 .7 cells and purified as described previously (11) (12) (13) (14) . Recombinant preparations of mu and human (hu) GM-CSF and muIL-4 (sp act, -108 U/mg each) (5) and huIL-6 (sp act, 5 x 106 U/mg) were kind gifts from Dr. David Urdal and Dr. Steven Gillis, Immunex Corp., Seattle, WA. Natural muCSF 1 (sp act, 2.3 x 107 U/mg) (5) was a kind gift from Dr. Richard K. Shadduck, University of Pittsburgh School of Medicine, Pittsburgh, PA. Recombinant huG-CSF (95% pure, sp act, >5 x 10' U/mg) (5) was a kind gift from Dr. Peter Ralph and Dr. Robert Drummond, Cetus Corp., Emeryville, CA. Recombinant huIL-1-a (sp act, 109 U/mg using the D10 cell assay) (6) was a kind gift from Dr. Peter T. Lomedico, Hoffman-La Roche, Nutley, NJ. The purified Ig fractions of anti-MIP-1 and anti-MIP-2 (17) were prepared from serum ofrabbits injected respectively with purified preparations of MIP-1 and MIP-2. Escherichia coli LPS was purchased from Sigma Chemical Co., St. Louis, MO.
Colony Assays
CFU-GM Unseparated mouse bone marrow cells (0.5, 0.75, and 1.0 x 105 cells/ml) and low density human bone marrow cells (1.0 x 105 cells/ml) were plated in standard 35-mm standard tissue culture dishes in 1 ml of 0.3% agar (Difco Laboratories, Inc., Detroit, MI) culture medium containing McCoy's 5A medium supplemented with additional essential and nonessential amino acids, glutamine, serine, asparagine, sodium pyruvate (Gibco Laboratories, Grand Island, NY) and 10% inactivated (56°C for 0.5 h) FCS (HyClone Laboratories, Logan, UT) with or without purified growth factors (5) . Purified murine CFU-GM were plated at 200 cells/ml in 0.4% agarose (16) . Serum-free culture conditions were as described elsewhere (18) . Culture dishes were incubated at 37°C in a humidified atmosphere flushed with 5% C02 at lowered (5%) 02 tension and scored after 7 d for colonies (>50 cells/aggregate) and clusters (5-50 cells/aggregate) for human and mouse cells, and also after 14 d for human cells . Day 7 and day 14 colonies appear to derive from different human CFU-GM progenitors (19, 20) and colonies plus clusters provide a more accurate estimate of the actual number ofprogenitor cells stimulated than sampling ofcolonies only (19) . Colony and cluster morphology were assessed in whole plates stained with a-naphthyl acetate esterase and luxol fast blue and counter-stained with hematoxylin (21) . CFU-GM in DNA synthesis (S-phase) were killed by pulse exposure to 50 uCi/ml high specific activity [3H]TdR (sp act, 20 Ci/ mmol; New England Nuclear, Boston, MA) as described (22, 23) .
BFU-E. Mouse bone marrow cells (2 x 105 cells/ml) were plated in standard 35-mm tissue culture dishes containing a 1-ml mixture of Iscove's modified Dulbeccds medium, 1.3 methylcellulose, 30% FCS, 5 x 10-5 M 2-ME, 0.1 mM hemin (Eastman Kodak Co., Rochester, NY), and 2 U (r)erythropoietin (Amgen Corp., Thousand Oaks, CA) (22) . Cultures were incubated as above for CFU-GM and scored after 7 d of incubation .
Statistics
The results are expressed as the mean t 1 SEM ofthree plates per point for the CFU-GM assay and four plates per point for the BFU-E assay. Levels of significance for comparisions between samples were determined using student's t distribution.
Results
Myelopoietic Enhancing Activities In Vitro ofMIP-1 and MIP-2. MIP-1 and MIP-2 were assessed alone and in combination, at various concentrations, for their influence on colony and cluster formation by mouse bone marrow CFU-GM stimulated with suboptimal concentrations of nmuCSF1 or rmuGM-CSR Representative results of one of two identical sets of experiments are shown in Table I . MIP-1 and MIP-2 each significantly enhanced colony, and colony plus cluster, formation stimulated by 10 U/ml of either nmuCSFl or rmuGM-CSR Maximal levels of enhancement were noted at 100-200 ng/ml MIP-1 or MIP-2 ( Table I ) and concentrations of up to 1,000 ng/ml of MIP-1 or MIP-2 did not further enhance colony or cluster formation (data not shown) . No synergy was observed when MIP-1 and MIP-2 were assayed in combination (Table I ). Neither MIP-1 nor MIP-2, at concentrations ranging from 100 to 300 ng/ml, stimulated colony or cluster formation of mouse marrow CFU-GM in the absence of an added source of CSF (Table II) . Both MIP-1 and MIP-2 enhanced colony and cluster formation of mouse marrow CFU-GM maximally stimulated by nmuCSF1 or rmuCSF1 (100 U/ml or either), but the percent enhancement noted was not as much as that seen when colonies and clusters were stimulated with suboptimal concentrations of either CSF (10 U/ml of each) ( Table  II) . The enhancing effects ofMIP-1 or MIP-2 were similar whether colonies or colonies plus clusters were evaluated except when 10 U/ml of nmuCSFl was used to stimulate the cells; in this case enhancement of colonies by MIP-1 or MIP-2 was greater than the enhancement for colonies plus clusters (Table II) . The enhancing effects of MIP-1 and MIP-2 were noted whether the cells were plated in the absence or presence of 10-6 M indomethacin (Table II , legend). The enhancing activity of MIP-1 or MIP-2 was also apparent in the absence of serum in the culture system, with 200 ng of each significantly enhancing colony and colony plus cluster formation by 67-89% in the presence of 100 U nmCSF1 and by 77-122% in the presence of 100 U rmuGM-CSF When the types ofcolonies and clusters enhanced by MIP-1 and MIP-2 were evaluated, it was evident that both those containing only macrophages, or containing both macrophages and neutrophils, were significantly (p < 0.001) enhanced by MIP-1 and MIP-2 (data for five separate experiments not shown) . Specificity ofMIP-1 andMIP-2 Myelopoietic EnhancingActivities. To substantiate that the enhancing effects noted were due to MIP-1 and MIP-2 themselves, the preparations ofMIP-1 and MIP-2 were each preincubated with purified Ig fractions ofrabbit anti-murine MIP-1 or rabbit anti-murine MIP-2 before their addition to cultures containing 10 U/ml of either nmuCSFl or rmuGM-CSR The representative results of one or two similar experiments are shown in Fig. 1 . The antibodies by themselves had no effect on CSFstimulated colony or cluster formation (p > 0.05) . Anti-MIP-1 neutralized the myelopoietic enhancing activity of MIP-1, but not of MIP-2, and anti-MIP-2 neutralized the myelopoietic enhancing activity of MIP-2, but not of MIP-1, suggesting that the enhancing effects of MIP-1 and MIP-2 were independent and not due to contaminating molecules. Results are expressed as the mean t 1 SEM, with numbers of experiments done shown in parentheses, for BDFj mouse bone marrow cells plated at 5 .0 x 104, 7 .5 x 104 , or 1 .0 x 10 cells/ml in the absence and presence of added CSF and in the absence or presence of 100-300 ng MIP-1 or MIP-2 . Results were similar regardless of the cell concentration plated or if cells were plated in the absence or presence of 10 -6 M indomethacin and were therefore pooled. The percent increases are based on control CFU-GM numbers of. 0 colonies and 0 to 8 t 1 colonies and clusters without CSF, 7 t 1 to 39 t 1 colonies and 30 t 1 to 120 t 10 colonies plus clusters with 10 U CSFA, 62 t 1 to 151 * 5 colonies and 109 t 6 to 313 t 13 colonies plus clusters with 100 U CSF-1, 19 t 1 to 49 t 2 colonies and 28 t 1 to 103 t 5 colonies plus clusters with 10 U GM-CSF, 31 t 1 to 67 t 2 colonies and 45 t 3 to 137 t 4 colonies plus clusters with 100 units GM-CSF, 8 t 1 to 15 t 3 colonies and 19 t 2 to 38 t 5 colonies plus clusters with 100 U G-CSF . 2 Increases for each experiment within these groups were statistically significant to ¢ < 0 .01 . 5 Increases for each experiment within these groups were statistically significant to P < 0 .05 . While MIP-1 and MIP-2 enhanced CFU-GM colony and cluster formation stimulated by nmuCSF1 and rmuGM-CSF as noted above (Tables I and II) , both MIP-1 and MIP-2 were without effect on colonies or clusters stimulated by rhuG-CSF (Table  11 ). Colonies and clusters stimulated by rhuG-CSF were >951 7o composed of only neutrophilic granulocytes . We also tested MIP-1 and MIP-2 for enhancement of erythroid progenitor cell proliferation by mouse bone marrow erythroid burst-forming units (BFU-E). In the absence of Epo, no BFU-E colonies formed in the absence or presence ofMIP-1 or MIP-2. Neither MIP-1 nor MIP-2, at concentrations ranging from 1 to 1,000 ng/ml, enhanced BFU-E colony numbers or size in the presence of 0.25-2.0 U of Epo (p > 0.05). Control BFU-E numbers formed in the absence of MIP-1 and MIP-2 but in the presence of 2.0 U of Epo were, respectively, 25 t 1 and 25 t 2 per 2 x 105 BDFI mouse bone marrow cells plated in two separate experiments.
The myelopoietic enhancing effects of MIP-1 and MIP-2 on mouse bone marrow cells were not mimicked by rhuIL-la, rmuIL-4, rhuIL-6, or E. coli LPS (data not shown) . rhuIL-la and rhuIL-6, both ofwhich are titered for activity on mouse cells, were each tested at 1, 5, and 10 ng/ml and were not found to significantly influence colony or cluster formation stimulated with 10 U/ml ofnmuCSFl or rmuGM-CSF, or 100 U/ml rhuG-CSF Moreover, neither 10 ng/ml of rhuIL-1a nor of rhuIL-6 significantly influenced colonies or clusters formed in the presence of 100 ng/ml MIP-1 or MIP-2 with 10 U/ml of nmuCSFl or rmuGM-CSE We have previously shown that rmuIL-4 only enhances mouse bone marrow neutrophil colony and cluster for-mation in the presence of rhuG-CSF; it does not enhance neutrophil, neutrophilmacrophage, or macrophage colony or cluster formation stimulated with nmuCSF1 or rmuGM-CSF (5) . E. coli LPS tested at 0.01-100,ug/ml (in 10-fold increments) in the absence or presence of 10 -6 M indomethacin did not enhance colony or cluster formation stimulated by 10 U/ml nmuCSFl or rmuGM-CSF. LPS did suppress CSFstimulated colonies and clusters in a dose-dependent fashion with up to 93% inhibition apparent with 100 t~g LPS/ml. The LPS-induced suppression was still apparent and only minimally counteracted when cells were plated with 10 -6 M indomethacin .
Influence ofMIP-1 andMIP-2 on PurifiedPbpulations ofMouse Marrow CFU-GM. Since CFU-GM make up <0.5% of the population ofunseparated marrow cells (as is apparent from the <0.5% colony and cluster cloning efficiency of cells plated in the presence of 100 Units/ml nmCSF1 or rmGM-CSF in Table II ) it was not possible to determine from the above studies whether MIP-1 and MIP-2 were acting directly on the CFU-GM, or indirectly through an action on accessory cells. To determine whether MIN and MIP-2 had direct acting effects on CFU-GM, mouse bone marrow cells were purified (16) and the preparations of these two mediators were evaluated for their influence on colony and cluster formation by 200 purified cells plated/milliliter and stimulated with 50 U/ml of either nmuCSFl or rmuGM-CSF. The results of one representative of two similar experiments are shown in Fig. 2 . The colony plus cluster cloning efficiencies of the various fractions ranged from 15 to 44% when cells were stimulated with nmuCSF1 and from 17 to 39% when cells were stimulated with rmuGM-CSF These concentrations of CSF (50 U/ml) result in maximal or near maximal stimulation of colony and cluster formation by purified CFU-GM when only one type of CSF is used, although combinations of CSFs can result in higher cloning efficiencies (3). MIP-1 and MIP-2 (100 ng/ml) each significantly enhanced (p at least <0.01 when compared with cells in that particular fraction cultured with control medium) CSFstimulated colony and cluster formation by purified CFU-GM in the various fractions (Fig . 2) . Cloning efficiencies ofup to 82 and 65% were respectively noted for cells plated in the presence ofMIP plus either nmuCSFl or rmuGM-CSF These results suggest that MIP-1 and MIP-2 probably exert direct acting effects on mouse marrow CFU-GM in vitro.
Cell Cycle-related Myelopoietic Enhancing Activities ofMIRI and MIP-2. To evaluate whether MIP-1 and MIP-2 had preferential effects on CFU-GM in S-phase or during non-S-phase portions of the cell cycle, mouse bone marrow cells were pulse treated with nonradioactive (cold) thymidine (shown to have no effect on subsequent colony or cluster formation by the cells [22, 23] ) or high specific activity tritiated thymidine before washing and plating in the presence of 10 or 100 U/ml ofnmuCSF1 or rmuGM-CSF and in the absence or presence of 100 ng/ml MIP-1 or MIP-2 . Table III shows the data from one of two experiments with similar results. Both MIP-1 and MIP-2 significantly enhanced colony and cluster formation by cells first pulsed with cold thymidine. In contrast, CFU-GM in DNA synthesis (S-phase) at the time of pulse exposure with high specific activity [3H]TdR are reproductively killed and only CFU-GM not in S-phase ofthe cell cycle at that time go on to proliferate in response to CSF to form a colony or cluster. MIP-1 and MIP-2 had no myelopoietic enhancing activity on cells that were first pulse treated with high specific activity [3H]TdR to FIGURE 2 . Influence of MIP-1 and MIP-2 on colony and cluster formation of purified mouse CFU-GM stimulated by nmuCSRl or rmuGM-CSF. Mouse CFU-GM were purified as described elsewhere (16) . remove S-phase CFU-GM . These results suggest that the myelopoietic enhancing activities of MIP-1 and MIP-2 are initiated mainly or entirely during the DNA synthetic phase of the CFU-GM cell cycle. Influence ofMIP-1 and MIP-2 on Colony and Cluster Formation by Human Bone Marrow CFU-GM. MIP-1 and MIP-2 (200 ng/ml) were evaluated for their effects on colony and cluster formation by CFU-GM present in the low density fraction of normal human bone marrow (Table IV) . Cells were plated at 105 cells/ml in the absence or presence of 100 U/ml rhuGM-CSF or rhuG-CSF and scored after 7 and 14 d ofincubation . Low density human bone marrow cells can form colonies and clusters in the absence of an exogenously added source of CSF, but the numbers of colonies and clusters formed are related to the number of cells plated and are a result of the endogenous release ofCSFs from marrow accessory cells (24) . In the two experiments shown, MIP-1 and MIP-2 in the absence of added CSF significantly enhanced colony formation when colonies formed in the absence of MIP, but not when colonies did not form in the absence of MIP MIP-1 and MIP-2 each enhanced cluster formation in the absence ofexogenously added CSF MIP-1 and MIP-2 significantly enhanced colony and cluster formation by day 7 and day 14 CFU-GM stimulated with rhuGM-CSF, but similar to the results noted for mouse colony and cluster formation stimulated by G-CSF (Table II) mice (11, 13) . MIP-1 acts as a prostaglandin-independent endogenous pyrogen when administered to mice (15) and is capable in vitro ofinducing chemokinesis ofhuman neutrophils and oftriggering adherent neutrophils to release hydrogen peroxide (11) . MIP-2 acts as a chemotactic agent for neutrophils and induces neutrophil degranulation of lysozyme, but not of beta-glucuronidase (13) .
The results presented here demonstrate a new and as yet unique role for MIP-1 and MIP-2 at the level of the granulocyte/macrophage progenitor cell . While MIP-1 and MIP-2 had no hematopoietic CSF activity when tested alone, they did significantly enhance colony and cluster formation by murine bone marrow CFU-GM costimulated with nmuCSF1 and rmuGM-CSF and by human bone marrow CFU-GM costimulated with rhuGM-CSF Studies using purified mouse marrow CFU-GM suggested that the myelopoietic enhancing effects of MIP-1 and MIP-2 were due to a direct effect on the CFU-GM itself. The exact manner and mechanism of action of MIP-1 and MIP-2 on CFU-GM remains to be determined, but the action appears to be mediated, or at least initiated, during S-phase of the cell cycle. The fact that MIP-1 and MIP-2 can act directly on CFU-GM does not however rule out the possibility that MIP-1 and MIP-2 might be able also to modulate myelopoiesis indirectly through an action on accessory cells.
A number of molecules without CSF activity can modulate myelopoiesis in a positive fashion, but the type of enhancing activity noted for MIP-1 and MIP-2 was not duplicated in our hands by IL-la, IL-6, or bacterial LPS. We had previously shown that IL-4 synergizes with G-CSF to enhance neutrophil colony formation (5), but MIP-1 and MIP-2 did not enhance the activity of rhuG-CSF against mouse or human bone marrow cells, and IL-4 does not enhance the activities ofnmuCSF1 and rmuGM-CSF (5). IL-5 acts as an eosinophil-CSF (25; Lu, L., Z. H. Lin, R. N. Shen, D. J. Warren, T Leemhuis, and H. E. Broxmeyer, manuscript in preparation) and MIP-1 and MIP-2 did not stimulate or enhance eosinophil colony or cluster formation in our studies. IL-2 has not been shown to directly enhance CFU-GM numbers (1) . In the type ofassay used in the present studies, cachectin/TNFa, lymphotoxin/TNFfl, interferons, and acidic isoferritin suppress colony formation (1, 4) . Activin enhances and inhibin suppresses BFU-E colony formation by an action mediated through T lymphocytes and monocytes, but has no effect on CFU-GM colony formation (10) , and MIP-1 and MIP-2 had no demonstratable effect on BFU-E colony formation. E-type prostaglandins 1 and 2 enhance Epo-dependent BFU-E, but suppress CSFdependent CFU-GM colony formation (21) . The reported effects of transforming growth factor 9 (26, 27) are also not consistent with the effects noted herein for MIP-1 and MIP-2 .
MIP-1 and MIP-2 have predicted amino acid sequence homology with a number ofother molecules activated in T lymphocytes, including LD78, JE, and TCA3 (12) . It will be of interest to see if these latter molecules have myelopoietic modulatory activities also. To be determined, as well, is whether MIP-1 and MIP-2 can act in vivo to enhance hematopoietic progenitor cell cycling and myelopoiesis .
Summary
Two recently identified and purified murine macrophage inflammatory proteins MIP-1 and MIP-2 were tested in vitro both alone, and in combination with purified recombinant (r) murine (mu) GM-CSF, natural (n)muCSF1, or rhuman (hu)G-
